Monitor Baker Brothers' selling activity via Form 4 filings and volume spikes ahead of the FDA advisory committee (July 30) and PDUFA (August 2). Heavy pre-catalyst selling would be a bearish signal. The going-concern warning and upcoming cash need increase the likelihood of dilutive capital raise post-FDA outcome, compounding the overhang risk.
Price Chart
Executive Summary
Replimune filed Amendment No. 1 to its S-3 shelf registration, enabling Baker Brothers affiliates to resell up to 25,103,489 shares (≈30% of current outstanding, including pre-funded warrants). The company receives no proceeds and has a going-concern warning with cash runway only through Q1 2027, while the FDA decision on the RP1 BLA is due August 2, 2026 (advisory committee July 30). This registration overhang adds downside risk ahead of the binary catalyst.
Key Facts
- 25,103,489 shares registered for resale by Baker Bros Life Sciences and 667, L.P. (Baker Bros. Advisors LP), including 14,058,153 shares issuable upon exercise of pre-funded warrants with nominal exercise prices.
- The selling stockholders beneficially own 25.94% of the company's shares as of March 31, 2026.
- Company's independent auditors included a going-concern explanatory paragraph in the FY2026 10-K; cash, equivalents and short-term investments will fund operations only into Q1 2027.
- FDA action date for RP1 BLA resubmission (advanced melanoma) is August 2, 2026, with an advisory committee meeting on July 30, 2026.
- Replimune will not receive any proceeds from the resale; all proceeds go to selling stockholders.
Financial Impact
Potential overhang of ≈$263M at $10.46/share (25.1M shares) — represents ~30% of current outstanding shares if all sold.
Risk Factors
- Resale of a large block (25.1M shares) could pressure the stock price, and the registration rights agreement allows selling at any time.
- FDA CRL on August 2 would likely trigger restructuring, impairing equity value further.
- Cash runway only into Q1 2027 forces near-term capital raising, likely dilutive, regardless of FDA outcome.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001104659-26-086680 |
| Document: tm2620954d2_ex5-1.htm | 0001104659-26-086680 |
| Document: tm2620954d2_ex23-1.htm | 0001104659-26-086680 |
| Document: 0001104659-26-086680-index-headers.html | 0001104659-26-086680 |
| Document: 0001104659-26-086680-index.html | 0001104659-26-086680 |
| Document: 0001104659-26-086680.txt | 0001104659-26-086680 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access